Therefore, chimeric antigen receptor (CAR) T cells have been engineered to target FGFR4 and CD276, thereby successfully reducing T cell exhaustion, enhancing T cell persistence, and restoring a robust anti-tumor immune response [45]. The gene discussed is FGFR4; the disease is neoplasm.